Skip to main content Skip to section navigation Skip to footer
LIXTE-logo-web-horz-black-190
  • Our Approach
  • Science
  • Programs
  • Team
  • Investor Information
✕
  • Our Approach
  • Science
  • Programs
  • Team
  • Investor Information

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote and Chart
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Apr 28, 2021 9:35 am EDT

Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14

Apr 13, 2021 9:35 am EDT

Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors

Mar 17, 2021 9:35 am EDT

Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24

Mar 3, 2021 9:35 am EST

Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference

Mar 2, 2021 10:30 am EST

Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering

Mar 1, 2021 8:45 am EST

Lixte Biotechnology Announces $4.19 Million Registered Direct Offering

Feb 24, 2021 9:35 am EST

Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference

Jan 19, 2021 9:35 am EST

Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer

Dec 1, 2020 12:30 pm EST

Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq

Nov 25, 2020 8:30 am EST

Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
Lixte Logo

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing innovative cancer therapies and oncology treatments using PP2A inhibition with LB-100.

CONTACT

LIXTE Biotechnology Holdings, Inc.
680 E Colorado Blvd., Suite 180
Pasadena, CA 91101

General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
Fax: (631) 982-5050
Email: info@lixte.com

LIXTE Biotechnology Holdings, Inc.
is publicly traded as LIXT.

Privacy Policy | Terms of Use

  • Our Approach
  • Science
  • Programs
  • Team
  • Investor Information
amazon behance bloglovin dribbble email facebook flickr github goodreads instagram linkedin medium meetup periscope phone pinterest reddit rss snapchat tiktok tripadvisor tumblr twitter vimeo whatsapp xing youtube
  • Facebook
  • LinkedIn
  • Twitter
© 2025 LIXTE Biotechnology Holdings, Inc. (LIXTE). All Rights Reserved. | Site by Third Eye Industries